Bernstein SocGen Group Reiterates Outperform Rating on Gilead Sciences (GILD) Following HIV Day
Tweet Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $105.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
